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Abstract
Long terminal repeat (LTR) elements are wide-spread in the human genome and have the potential to act as promoters and
enhancers. Their expression is therefore under tight epigenetic control. We previously reported in classical Hodgkin
Lymphoma (cHL) that a member of the THE1B class of LTR elements acted as a promoter for the proto-oncogene and
growth factor receptor gene CSF1R and that expression of this gene is required for cHL tumour survival. However, to which
extent and how such elements participate in globally shaping the unique cHL gene expression programme is unknown. To
address this question we mapped the genome-wide activation of THE1-LTRs in cHL cells using a targeted next generation
sequencing approach (RACE-Seq). Integration of these data with global gene expression data from cHL and control B cell
lines showed a unique pattern of LTR activation impacting on gene expression, including genes associated with the cHL
phenotype. We also show that global LTR activation is induced by strong inflammatory stimuli. Together these results
demonstrate that LTR activation provides an additional layer of gene deregulation in classical Hodgkin lymphoma and
highlight the potential impact of genome-wide LTR activation in other inflammatory diseases.
Introduction
Human endogenous retroviruses (HERVs) account for 8%
of the human genome originating from ancient retroviral
germ line infections arising over 35 million years ago and
persisting throughout mammalian evolution [1, 2]. Mam-
malian apparent long terminal repeat (LTR) retro-
transposons (MaLR) are the largest HERV class (48%) [2]
and consist mainly of solitary LTRs spread throughout the
genome [1]. LTRs need to be strictly regulated due to their
potential to act as RNA-polymerase II-dependent promoters
and enhancers [3]. LTR activation in disease can lead to
dysregulation of oncogene expression [4]. We showed this
function of LTRs for the first time in malignant Hodgkin–/
Reed–Sternberg (HRS) cells in classical Hodgkin lym-
phoma (cHL) [5] which exhibit a highly dysregulated
inflammatory gene expression programme unrelated to that
of normal B-cells [6]. Due to the loss of B-cell receptor
(BCR) expression, HRS cells developed alternative survival
mechanisms, one of which is the co-expression of CSF1 and
CSF1R [5]. We showed that CSF1R expression is driven by
an aberrantly activated upstream THE1B LTR which
belongs to the MalR family of repeat elements. Activation
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of this LTR was associated with a down-regulation of
expression of the co-repressor ETO2 (CBFA2T3) and NF-
κB-activation [5]. Using 3′ rapid amplification of cDNA
ends (RACE) we also showed that THE1B family LTR
activation in HRS cells was wide-spread. However, which
of these THE1B LTRs served as promoters in HL, and the
impact of THE1-LTR activation on global gene expression
was not investigated.
To answer this question, we designed a genome-wide
targeted sequencing assay to further investigate the activa-
tion of THE1-LTRs in HRS cell lines, primary cells and
control B-cell lines. We find unique patterns of HRS cell-
specific activation of THE1B-LTR promoters at genes
associated with the cHL phenotype and show that genome-
wide LTR activation is triggered by the activation of NF-κB
and broader inflammatory stimuli. Our results highlight the
potential for THE1B-LTRs to have widespread influence on
gene regulation in cHL and other inflammatory diseases.
Methods
Cell culture
cHL (L428, L1236 and KM-H2), Burkitt’s lymphoma
(Namalwa) and B-cell precursor leukaemia (Reh) cell lines
were cultured as previously described [5]. The 293T cell
line was cultured in DMEM with 10% FCS, 2 mM Gluta-
mine, plus P/S. All cultures were incubated at 37 °C in a
humidified incubator with 5% CO2.
Gene expression analysis
RNA was isolated using a Nucleospin RNA extraction
column with on-column DNase treatment (Machery Nagel,
France). RT-qPCR was performed using Sybr® green master
mix (Sigma) and was run on an Applied Biosystems Ste-
pOne Plus RT PCR system with the default PCR pro-
gramme (Primer sequences, see supplements). All
expression values were normalised to GAPDH expression
and a Student's t-test was used to test statistical significance
for data with a normal distribution.
RNA sequencing libraries were produced in duplicate
using the TruSeq Stranded Total RNA Library Prep Kit
with Ribo-Zero Human/Mouse/Rat (Illumina). Next Gen-
eration Sequencing (NGS) was carried out using Illumina
HiSeq 2500 and NextSeq 500 instruments.
RACE-Seq
RACE was carried out based on the ExactSTART™
Eukaryotic mRNA 5′-RACE and 3′-RACE Kit (Epicentre)
and supplied protocol. Due to discontinuation of the
Tobacco Acid Pyrophosphatase enzyme some modifications
were made (see Supplementary materials). A biotinylated
primer complementary to a highly conserved transcribed
region of the THE1B LTR was used to synthesise RACE
fragments. Fragments were then pulled down using mag-
netic streptavidin beads, amplified and tagged with indexed
Illumina sequencing adaptors to allow for direct next gen-
eration sequencing (NGS).
Western blotting
Total protein was extracted using RIPA buffer with protease
inhibitors added (1:100). Nuclear protein extraction was
carried out using the Active Motif Nuclear Extraction Kit.
Western blotting was performed by blotting Mini-
PROTEAN TGX 5–20% gradient gels (Bio-Rad) on nitro-
cellulose membranes using the Trans-Blot Turbo system
(Bio-Rad). Blocking was carried out using 5% milk in
TBST. Antibodies are listed in Supplementary Materials.
Phorbol myristate acetate (PMA) treatment
PMA treatment was at 2 ng/ml media at a cell density of 1 ×
106/ml.
RNA interference
siRNA knockdown was performed by re-suspending L1236
and KM-H2 cells at 1 × 107 cells/ml in 700 µl Opti-MEM
medium (Sigma) and mixed with siRNA to a final con-
centration of 200 nM in a 0.4 mm electroporation cuvette
and electroporated using a Gene-Pulser X-cell (Bio-Rad)
(L1236–960 µF, 0.18 kV and KM-H2–50 μF, 0.5 kV).
IκKβ(EE) cloning
IκKβ(EE) DNA was excised from a plasmid described in
ref. [5] and transferred to the PCW57.1 vector (Addgene
plasmid # 41393) using Gateway cloning. Viral particles
were produced using Hek293T cells as described [7]. Reh
cells were transduced by spin infection (1500×g, 2 h) and
puromycin (1 μg/ml) selected for 1 week. Following dox-
ycycline induction (2 μg/ml) for 48 h, cells were purified by
fluorescence-activated cell sorting for GFP labelling and
immediately used for experiments.
Laser capture microdissection and low input RNA-
Seq library preparation
Frozen tumour tissue was fixed for 10 min with 100%
ethanol and air dried. Following fixation 200–400 HRS or
surrounding bystander cells were excised using a Zeiss
PALM LCM system and catapulted onto adhesive caps
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(415190-9191-000—Zeiss). Cell lysis, RNA extraction and
purification were performed using the absolutely RNA
Nanoprep Kit (400753—Agilent). RNA-Seq libraries were
produced using the SMARTer Stranded Total RNA-Seq Kit
v2—Pico input Mammalian (Takara Bio). The libraries
were used for both rtPCR as previously described and were
sequenced on an Illumina NextSeq 500 at the Genomics
Birmingham facility.
ChIP-Seq
ChIP was performed as previously described [8] with slight
modifications, i.e. using 5 × 106 cells, 15 µl Protein-G
Dynabeads (Invitrogen), 2 µg H3K4me3 millipore 04745
antibody, and using phenol–chloroform DNA extraction.
Detailed methods are available in Supplementary Methods.
Libraries were generated using the Kapa Hyperprep Kit
(Kapa Biosystems) according to manufacturer’s instructions
and sequenced using an Illumina HiSeq 2500 sequencer.
Data analysis
Full details of bioinformatics analysis can be found in
the Supplementary Materials.
Results
cHL cell lines display a global activation of MalR
long terminal repeat elements
To identify the global pattern of LTR-driven transcripts in
HRS cells we designed a genome-wide 5′ RACE-Seq
screen using a primer matching a highly conserved, tran-
scribed LTR region. This sequence is shared between
THE1A, THE1B, THE1C, and THE1D LTRs, and also
amplifies MSTA and MSTB LTRs (Fig. 1a and S1A). RACE
products from L428, L1236 and KM-H2 cHL cell lines
expressing the LTR-driven CSF1R, and Reh and Namalwa
cell lines representing non-Hodgkin B cells as controls
(Fig. 1b) were analysed by NGS. In agreement with our
previous work [5], 5′ RACE-Seq showed a peak corre-
sponding to the CSF1R-LTR in the genome of all cHL cell
lines but not in controls (Fig. 1c). The consensus THE1B
primer (Fig. 1a) amplified a broad library of related LTR
classes, including THE1B, THE1D, THE1C, THE1A, and
MSTA (Fig. 1d and S1B). As expected, cHL cell lines dis-
played a bias towards THE1B activation (over 50% of the
detected LTRs) when compared to the balance of LTR
classes in the genome and to those active in the control cell
lines (Fig. 1d and S1B). Only 10% of the LTRs perfectly
aligned to the primer sequence, with amplified LTRs having
up to eight mismatches (Fig. S1C). Due to the high
proportion of mismatches, only 7–30% of peaks were
shared between all three RACE-Seq replicates in each cell
line (Fig. S1D). This variation was likely to be due to
variations in the crucial first extension step, we therefore
used a conservative approach by carrying out all further
analysis on LTRs identified in at least two out of the three
replicates.
To identify a cHL cell-specific pattern of LTR activation,
we overlapped merged RACE-Seq peaks from all three cHL
cell lines with the merged peaks from the two control cell
lines (Fig. 1e). This analysis highlighted 1836 cHL cell-
specific active LTRs and 413 LTRs specific to the control
cell lines. Additionally, we identified 373 activated LTRs
shared between cHL cell lines (of which 224 are unique to
HL) but also LTRs unique for each cell line (Fig. 1f), a
variation that was significant based on hypergeometric
analysis (p < 0.01). To find similarities between the cHL
cell lines, we performed a clustering analysis based on a
DICE index score which was calculated for each pair
(Fig. 1g). This analysis showed that the cHL cell line LTR-
profiles clustered together, away from the controls.
LTR activation contributes to global deregulation of
gene expression in cHL cells
The majority of transcribed LTRs were located in intra-
genic and inter-genic regions (Figs. 2a and S2F) with 1–3%
located at the transcription start site (TSS) of expressed
genes (Fig. S2F). To investigate whether LTRs could act as
promoters, we determined the gene expression profiles of
the cHL cell lines using RNA-Seq (Fig. S2A, B) and plotted
the RNA-Seq signal around active LTRs outside of pro-
moter regions (defined as 1 kb to +100 bp from the TSS),
using strand information inferred from Repeat Masker
annotation (Fig. 2b). The previously mapped HL-specific
LTR-driven transcript of CSF1R [9] is shown as control
(Fig. S2C). An RNA-Seq signal was observed at active
LTRs and stretched downstream on the sense strand. Only a
small proportion of LTR-driven anti-sense transcripts were
observed. Further to this analysis, we performed H3K4me3
ChIP-Seq in L428 cells and showed an enrichment of
H3K4me3 at active LTRs (Figs. S2D and E) supporting the
idea that these LTRs act as promoters.
HRS cells show a vastly different gene expression pat-
tern to B lineage cells as shown by clustering analysis of
RNA-Seq data (Fig. S2G). To examine whether active
LTRs increased expression of their nearest genes, we
clustered correlations of gene expression data for those
genes closest to active LTRs. HRS and control cells clus-
tered separately based solely on the expression of LTR-
associated genes (Fig. S2G and S2H, for full list of RACE
peaks and closest gene see Supplementary dataset 1). To
link the active LTRs with cell-type-specific gene
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expression, we plotted the expression of LTR-associated
genes in relation to the fold difference between HRS and
control cell lines (Fig. 2c). This analysis showed a sig-
nificant proportion of active LTRs close to the genes up-
regulated in each of the HRS cell lines (red) compared to
the control cell lines (green).
To understand how active LTRs influence expression of
individual genes and contribute to the HRS cell phenotype,
we manually screened active LTRs to examine surrounding
changes in RNA expression. THE1 LTRs produced four
types of transcripts: (1) intergenic, acting as an upstream
promoter up-regulating expression of a gene, (2) intragenic,
with the LTR promoter producing a new shorter isoform of
a gene, (3) anti-sense, leading to down-regulation of gene
expression, or (4) intergenic as previously un-annotated
long non-coding RNA (lncRNAs). Examples of each type
of transcript are shown in Fig S3 and were validated by
qPCR (Fig. S4A-G). Taken together, our data show a
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genome-wide transcriptional activation of THE1 LTR
members in cHL cells with a number of these elements
altering the transcriptional output of their associated genes.
LTR activation drives the expression of genes
associated with cHL pathology
We next determined whether any of the newly discovered
LTR-driven genes were associated with the HRS cell phe-
notype. The TNFRSF11A (tumour necrosis factor receptor
superfamily member 11a) gene has been previously shown
to be upregulated in cHL [10]. Our data showed an active
THE1B LTR 1.2 kb upstream of TNFRSF11A producing a
transcript in the L1236 cell line and also a weak transcript in
the L428 cell line (Fig. 3a), leading to an increase in
expression (Fig. 3b, c). To determine whether the LTR
drives a full length transcript, we knocked down the
TNFRSF11A mRNA with an siRNA designed against exon
7 and found that this also reduced the LTR-driven transcript
(Fig. S5A and B). Interestingly, we identified a secondary
mechanism of control for LTR-driven TNFRSF11A
expression in the L1236 cell line. This specific LTR con-
tains a NFI transcription factor-binding site (Fig. S6A).
Nuclear Factor I X (NFIX) is highly expressed in L1236
cells, and following siRNA knockdown the expression of
TNFRSF11A and its LTR transcript were significantly
reduced (Figs. S6B and C).
A THE1D LTR 20 kb upstream of theWNT5A gene drives
a transcript in the KM-H2 cell line (Fig. 3d–f) producing both
a spliced and a lncRNA (annotated by GENCODE as RP11-
875H7.5) (Fig. 3d and S5C). siRNA knockdown of WNT5A
(Fig. 3g) leads to a significant increase in cell doubling time
(Fig. 3h), demonstrating a functional role for another active
LTR in determining the HRS cell phenotype.
LTR-driven transcripts can be detected in primary
HRS cells
To examine whether the LTR-driven pattern of gene acti-
vation identified in the cell lines was also present in primary
cells, we analysed RNA from frozen HL tumours. The
TNFRSF11A LTR transcript was significantly up-regulated
in three out of the five patient samples, correlating with up-
regulation of the gene in two out of the three cell lines
(Fig. 4a and S7A). The WNT5A LTR-driven transcript was
expressed in two out of the five samples which again cor-
related with WNT5A up-regulation (Fig. 4a and S7A). A HL
tumour can be composed of as little as 1% HRS cells [11].
We therefore analysed RNA from laser capture micro-
dissected (LCM) HRS cells and surrounding bystander cells
from five different tumours. RT-PCR showed the expres-
sion of a 86 bp band indicative for the TNFRSF11A LTR
transcript in one sample and the 179 bp band indicating the
WNT5A LTR transcript in another (Fig. 4b). We further
characterised LCM cells by RNA-Seq and confirmed that
isolated HRS cells expressed common up-regulated genes
and the HRS-specific up-regulated gene signature identified
in [12] (Figs. S7 B, C and D). All primary HRS cells spe-
cifically expressed TNFRSF8 (CD30) and most HRS and
bystander cells expressed CD40 (Figs. S7E and F), high-
lighting the quality of our data However, only a subset of
tumours expressed LTR-driven TNFRSF11A and WNT5A
transcripts (Fig. 4c). Further to our finding that NFIX reg-
ulates the TNFRSF11A-LTR the expression of NFIX in the
particular LCM sample correlated with the presence of a
TNFRSF11A-LTR transcript (Fig. S7G).
THE1 LTRs are activated by inflammatory stimuli
Our previous analyses [5] identified a NF-κB-binding motif
in the CSF1R-LTR (Fig. S8A) and demonstrated that NF-
κB signalling plus knock-down of CBFA2T3 (ETO2) acti-
vated this element in non-Hodgkin cells. To determine
whether constitutive NF-κB signalling alone could induce
global THE1B LTR activation, we transduced the non-
Hodgkin Reh cell line with a doxycycline inducible acti-
vating IKKβ (IKKβ(EE)) (Figs. S8B, C and D) [13] fol-
lowed by RACE-Seq experiments. Results were filtered for
those present in at least two replicates (Fig. S8E). NF-κB
activation resulted in activation of 620 additional LTRs as
compared to un-induced and GFP-only induced cells
(Fig. S8F). 161 of the NF-κB-driven LTRs were also
expressed in HRS cells compared with 16 LTRs from un-
induced cells (Fig. S8G). However, a further 531 LTRs
were being activated specifically in Reh cells (Fig. S8G),
implying that THE1 LTR activation across the genome is
controlled by cell-type-specific regulatory mechanisms such
as CBFA2T3 expression.
HRS cells display a strong inflammatory gene expression
signature [6] as seen in the KEGG pathway analysis based
on our RNA-Seq data (Fig. S9A). To study the impact of a
broader inflammatory stimulus on LTR activation, Reh cells
were treated with phorbol-12-myristate 13-acetate (PMA), a
Fig. 2 LTR activation contributes to global deregulation of gene
expression in cHL cell lines. a Annotation of expressed LTRs iden-
tified by RACE-Seq to their respective genomic regions and annota-
tion of all RepeatMasker MaLR family LTRs for comparison. b
Average profiles produced using RNA-Seq data centred on active
LTRs identified by THE1B RACE-Seq and that were selected as
upstream of genes (i.e. as having the nearest downstream gene on the
same strand, and outside of promoter regions defined as 1 kb to +100
bp from the TSS), orientated based on LTR strand. ‘N’ represents
number of LTRs applying to these constraints. c Plot of fold-change of
gene expression obtained by RNA-Seq for each of the HRS cell lines
over each of the control cell lines. Active LTRs close to these genes
were plotted based on the gene expression fold-change axis. Sig-
nificance of LTRs associated with upregulated genes tested using a
hypergeometric test
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potent activator of protein kinase C (PKC) for 8 or 16 h
[14]. PKC activation drives multiple pathways linked to
inflammation and tumour growth, many of which are also
upregulated in HRS cells [15]. The CSF1R LTR was up-
regulated at both time points with a peak at 8 h (Fig. 5a)
whereby cells stopped growing in the presence of PMA
A
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(Fig. S9B). Crucially, PMA treatment also led to the rapid
loss of CBFA2T3 expression (Fig. 5b). RNA-Seq analysis
showed the expected activation of inflammatory response
genes (Fig. S9D and E) with a number of them overlapping
with those active in HRS cells, such as CCL4 and RELB
(Fig. S9F and G). Triplicate RACE-Seq data obtained after
8 h of treatment were again filtered for high confidence
peaks (Fig. S9C) and confirmed activation of the CSF1R
LTR (Fig. 5c). Expression of 235 cHL cell-specific LTRs
was induced by PMA treatment but a further additional 820
LTRs were also activated, again demonstrating that acti-
vation was cell-type specific (Fig. 5d). Integration of
RACE-Seq with RNA-Seq data demonstrated that total
gene expression patterns of the different cell lines clustered
based on the different cell types (Fig. 5e). However, the
analysis of LTR-associated genes showed that gene
expression patterns in Reh+PMA cells started to correlate
closer with HRS cells, with genes both being up-regulated
and down-regulated (brackets in Fig. S9F). In addition, we
observed an enrichment of up-regulated genes near PMA-
activated LTRs (Fig.5f). To establish whether the genes
upregulated by PMA-inducible LTRs were also up-
regulated by LTRs in HRS cell lines, we ranked the gene
expression fold change of several HRS cell lines over Reh
and aligned ranked genes with the presence of neighbouring
LTRs (Fig. 5g). This analysis showed that PMA treatment
induced expression of LTRs associated with up-regulated
genes in cHL.
Fig. 3 TNFRSF11A and WNT5A are expressed from active THE1B
and THE1D LTRs. a UCSC genome browser screenshot showing a
THE1B LTR acting as a promoter for the TNFRSF11A gene in L1236
and L428 cHL cell lines but not in primary CD19+ B cells [27].
b Normalised RNA-Seq FPKM values showing expression of
TNFRSF11A. c qPCR gene expression analysis showing expression of
a transcript between exon 2 and 3 and also between the upstream LTR
and exon 2. Three biological replicates (p < 0.05 L1236 vs. control cell
lines, paired Student's t-test). d UCSC genome browser screenshot
showing an LTR identified by RACE-Seq in the KM-H2 cell line
which produces a transcript of the WNT5A gene, shown by RNA-Seq
read alignment. Compared to Primary CD19+ B cell RNA-Seq [27].
e Normalised RNA-Seq FPKM values showing expression of WNT5A.
f qPCR gene expression analysis showing expression of a transcript
between exon 2 and 3 and also between the upstream LTR and exon 2
of WNT5A. Three biological replicates (p < 0.01 KM-H2 vs. control
cell lines, paired Student's t-test). g WNT5A protein measured by
western blot following siRNA knockdown compared to non-targeting
control. h Cell doubling time following siRNA knockdown of
WNT5A. Three biological replicates (p < 0.01, paired Student's t-test)
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LTR transcripts can be detected
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and HRS cells. a qPCR
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extracted from frozen cHL
tumour samples (P1–P5) and
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Three technical replicates (*p <
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1470 B. Edginton-White et al.
Re
h+
PM
A/
Re
h 
ex
pr
es
si
on
 F
D
Reh+PMA/Reh
exp FD
Reh+PMA
LTR
Reh
LTR
L428/Reh
expFD
Reh + PMA
LTR
L1236/Reh
expFD
Reh + PMA
LTR
Reh + PMA
LTR
L4
28
/R
eh
 e
xp
re
ss
io
n 
FD
L1
23
6/
Re
h 
ex
pr
es
si
on
 F
D
KM
-H
2/
Re
h 
ex
pr
es
si
on
 F
D
KM-H2/Reh
expFD
A B
C
D
F G
HL
Reh
Reh+PMA
115
1755820
174
49
184
235
p<0.05Expressed LTRs
chr5:
5 kb hg19
149,465,000 149,470,000
Namalwa
Reh
L428
KM-H2
L1236
CSF1R
Controls
HRS 
cells
RACE-Seq Reh + PMA
Pearson
Correlaon
0.75 0.850.95
Namalwa
Reh
KM-H2
L428
Reh + PMA
L1236
N
am
alw
a
R
eh
K
M
-H
2
L428
R
eh + P
M
A
L1236
E
p<1.1x10-9 p=0.044 p=0.005 p=0.022 p=3.19x10-4
Genes
Reh Reh + PMA 
8 hours
Reh + PMA 
16 hours
0.00
0.02
0.04
0.06
0.08
Ex
pr
es
si
on
 R
el
at
iv
e 
to
 G
A
PD
H
CSF1R LTR
Reh
0
5
10
15
20
Ex
pr
es
si
on
 R
el
at
iv
e 
to
 G
A
PD
H
CBFA2T3
Reh + PMA 
8 hours
Reh + PMA 
16 hours
Global long terminal repeat activation participates in establishing the unique gene expression. . . 1471
Discussion
Global THE1 long terminal repeat element activation
contributes to deregulation of gene expression in
classical Hodgkin lymphoma
In our previous work, we observed wide-spread activation
of LTR-associated transcripts in cHL [5], suggesting that
LTR activation could be playing a wider role in driving
cHL-specific gene expression. Here we used a targeted
approach to analyse the global activation of the THE1 class
of LTRs in cHL cell lines and primary material. In con-
cordance with other studies (reviewed by Babaian and
Mager [4]) we identified four types of LTR-driven tran-
scripts and showed the up-regulation of cHL-specific genes
near active LTRs, thus contributing to the overall expres-
sion pattern of each cell line. However, while there is a
shared cHL pattern of LTR activation, we also observed
cellular heterogeneity within the different cell lines, as well
as in the tumour cell population. The reason for this het-
erogeneity is unclear, but may originate from cell-type-
specific LTR activation as seen in our stimulation experi-
ments. It should also be noted that LTRs could act as
enhancers of their nearest genes, further deregulating gene
expression from a distance, contributing to the correlation
seen in Fig. 2c.
HRS-specific genes transcribed from activated LTRs
play a role in determining the cHL phenotype
We identified three protein-coding genes transcribed from
an LTR promoter in cHL; NLRP1, TNFRSF11A, and
WNT5A. We focused on TNFRSF11A and WNT5A as their
upregulation has previously been reported in cHL [6, 10,
16]. TNFRSF11A is up-regulated in an average of 75% of
HRS cells from primary tumour samples [6, 10]. Our work
agrees with this finding and identifies an active THE1B LTR
as the molecular mechanism of up-regulation. TNFRSF11A
is a member of the TNF receptor family and binds
TNFSF11A (RANKL) [17] which up-regulates signalling in
a number of pathways, including NF-κB and JNK [17, 18].
In HRS cells, stimulation of TNFRSF11A signalling by
TNFSF11A increases NF-κB-activation [10], leading to an
increase in inflammatory signalling, thus potentially form-
ing part of an autoregulatory loop through LTR activation.
The aberrant WNT5A transcript in HRS cells also origi-
nates from an upstream THE1D LTR. WNT ligands are
involved in development and many cellular processes [19]
WNT5A activates a β-catenin independent pathway driving
metastasis of gastric, brain, colon, and breast cancer [20–
22]. The up-regulation of WNT5A in HRS cells within a
proportion of tumours has been noted [12, 16, 23] and a
recent study implicated WNT5A in cell migration in HL
[16]. WNT5A interacts with the Fzd5 receptor, leading to
activation of RHOA which promotes motility in HRS cells
[23]. Our knock-down experiments indicate that the LTR-
driven transcript WNT5A may play a role in growth rate
regulation in a subset of cHL.
THE1 LTRs respond to inflammatory stimuli
The CSF1R LTR could be activated in non-Hodgkin cell by
a combination of NF-κB activation and knockdown of the
transcriptional repressor CBFA2T3 [4]. Both these condi-
tions mirror the status of HRS cells in which NF-kB is
constitutively activated and CBFA2T3 expression is fre-
quently lost [4]. Here we show that induction of NF-κB
activity alone resulted in the expression of a large number
of LTRs. However, only a small proportion of these LTRs
were also expressed in the HRS cell lines and the CSF1R
LTR was not activated. This finding highlights the multiple
levels of cell-type-specific control of LTR activation which
is further supported by our observation that the
TNFRSF11A LTR requires cell-type-specific NFIX
expression to be transcriptionally active.
PMA activates a variety of different signalling
pathways terminating at different inducible
transcription factors [14] and induces expression of many
more THE1 LTRs than NF-κB alone. The induction of
ERV-expression by treatment with PMA has been
shown previously, but not on a genome-wide scale, and the
mechanism of induction was unclear [24–26].
Fig. 5 Treatment of the Reh cell line with PMA induces global THE1B
LTR activation. a Treatment of Reh cells with 2 ng/ml PMA for 8 or
16 h followed by measurement of CSF1R-LTR expression by qPCR.
Three biological replicates. (p < 0.05 PMA treated vs. untreated, paired
Student's t-test) b CBFA2T3 gene expression measured by qPCR
following treatment of Reh cells with 2 ng/ml PMA for 8 or 16 h.
Three biological replicates (p < 0.05 PMA treated vs. untreated, paired
Student's t-test). c UCSC genome browser screenshot showing align-
ment of RACE-Seq reads to the CSF1R-LTR following PMA treatment
of Reh cells. d Overlap of RACE-Seq LTR peaks from Reh cells
±PMA treatment with merged peaks from the 3 HRS cell lines.
e Hierarchical unsupervised clustering of Pearson correlation of gene
expression patterns. f Fold-change of gene expression before and after
PMA treatment with the presence of active LTRs close to these genes
plotted based on the gene expression fold-change axis. g Fold-change
of gene expression obtained by RNA-Seq for each HRS cell line over
Reh with the presence of active PMA induced LTRs close to these
genes plotted based on the gene expression fold-change axis. Sig-
nificance of LTRs associated with upregulated genes tested using a
hypergeometric test
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Combined with the evidence for LTR-driven gene expres-
sion in this study, our findings have significant implications
for control of gene expression in any tissue or disease with a
high level of inflammation.
Our data support the idea that an initial inflammatory
stimulus could act to drive widespread changes in gene
expression as a result of LTR activation. The presence of
THE1 transcripts may be a marker for such a chronic
condition. Transcribed LTRs pose a significant threat to
correct regulation of gene expression and as shown here,
contribute to the establishment of a tumour-specific tran-
scriptional network potentially driving survival and growth
of HRS cells. Global LTR activation through chronic
inflammatory signalling therefore has broad implications
for gene regulation in many inflammatory diseases.
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